CG Oncology (CGON) Free Cash Flow (2023 - 2026)
CG Oncology (CGON) reported Free Cash Flow of -$57.2 million for Q1 2026, down 95.28% on a YoY basis from -$1.2 billion in Q1 2025, and down 57.79% quarter-over-quarter from -$36.3 million in Q4 2025.
CG Oncology (CGON) Free Cash Flow (2023 - 2026) Analysis & Trends
CG Oncology has reported Free Cash Flow for 4 years, with the latest figure at -$57.2 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 95.28% year-over-year to -$57.2 million; the trailing twelve-month figure through Mar 2026 stood at -$160.4 million (down 95.08% YoY), and the FY2025 full-year result was -$132.5 million, down 67.81% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$57.2 million, down from -$36.3 million in the prior quarter.
- The five-year high for Free Cash Flow was -$8.0 million in Q1 2023, with the low at -$57.2 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$24.2 million across 4 years, with a median of -$20.9 million in 2024.
- Annual changes were most pronounced in 2024 — Free Cash Flow tumbled 225.87% — and 2025, when it decreased 12.56%.
- CG Oncology's Free Cash Flow stood at -$14.6 million in 2023, then slumped by 42.51% to -$20.9 million in 2024, then slumped by 73.7% to -$36.3 million in 2025, then plunged by 57.79% to -$57.2 million in 2026.
- The last three Free Cash Flow figures came in at -$57.2 million (Q1 2026), -$36.3 million (Q4 2025), and -$39.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | CG Oncology | 5.16 Bn | 5.16 Bn | -1.88 Mn | -57.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -57.20 Mn |
| Mar 31, 2026 | -57.20 Mn |
| Dec 31, 2025 | -36.25 Mn |
| Dec 31, 2025 | -36.25 Mn |
| Sep 30, 2025 | -39.00 Mn |
| Sep 30, 2025 | -39.00 Mn |
| Jun 30, 2025 | -27.94 Mn |
| Jun 30, 2025 | -27.94 Mn |
| Mar 31, 2025 | -29.29 Mn |
| Mar 31, 2025 | -29.29 Mn |
| Dec 31, 2024 | -20.87 Mn |
| Dec 31, 2024 | -20.87 Mn |
| Sep 30, 2024 | -15.92 Mn |
| Sep 30, 2024 | -15.92 Mn |
| Jun 30, 2024 | -16.13 Mn |
| Jun 30, 2024 | -16.13 Mn |
| Mar 31, 2024 | -26.02 Mn |
| Mar 31, 2024 | -26.02 Mn |
| Dec 31, 2023 | -14.65 Mn |
| Dec 31, 2023 | -14.65 Mn |